Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years
Double Blind Study to Evaluate the Safety and Efficacy of 400 mg Twice Daily Rifamycin SV MMX® Added to Standard Oral Rehydration Therapy (ORT) Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 12 to 17 Years
Sponsor: RedHill Biopharma Limited
A PHASE2 clinical study on Traveler's Diarrhea, this trial is ongoing. The trial is conducted by RedHill Biopharma Limited and has accumulated 9 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Unknown PHASE2
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Feb 2026 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
May 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE2
▶ Show 4 earlier versions
-
Feb 2021 — May 2022 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- RedHill Biopharma Limited
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.